Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis

INTRODUCTION: The combination of pembrolizumab and axitinib has recently been approved as a first‐line treatment for previously untreated metastatic renal cell carcinoma. However, immune‐related adverse events are not well known. CASE PRESENTATION: A 65‐year‐old male was diagnosed with renal cell ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Shunsuke, Nakamura, Masaki, Chujo, Satomi, Ooki, Ryousuke, Inoue, Yasushi, Horiuchi, Hajime, Morikawa, Teppei, Uchino, Keita, Igarashi, Atsuyuki, Shiga, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560444/
https://www.ncbi.nlm.nih.gov/pubmed/34755064
http://dx.doi.org/10.1002/iju5.12356
_version_ 1784592934442631168
author Imai, Shunsuke
Nakamura, Masaki
Chujo, Satomi
Ooki, Ryousuke
Inoue, Yasushi
Horiuchi, Hajime
Morikawa, Teppei
Uchino, Keita
Igarashi, Atsuyuki
Shiga, Yoshiyuki
author_facet Imai, Shunsuke
Nakamura, Masaki
Chujo, Satomi
Ooki, Ryousuke
Inoue, Yasushi
Horiuchi, Hajime
Morikawa, Teppei
Uchino, Keita
Igarashi, Atsuyuki
Shiga, Yoshiyuki
author_sort Imai, Shunsuke
collection PubMed
description INTRODUCTION: The combination of pembrolizumab and axitinib has recently been approved as a first‐line treatment for previously untreated metastatic renal cell carcinoma. However, immune‐related adverse events are not well known. CASE PRESENTATION: A 65‐year‐old male was diagnosed with renal cell carcinoma with metastases to the brain and lungs. The patient had a medical history of stasis dermatitis. During the combined treatment of pembrolizumab and axitinib, blisters appeared on the lower extremities. Skin biopsy revealed septal panniculitis, pustules, and perivascular lymphocytic and neutrophilic infiltration of the skin, and the patient was diagnosed with immune‐related dermatitis. The dermatitis improved with oral prednisolone treatment. CONCLUSION: A case of immune‐related dermatitis during combinatorial treatment with pembrolizumab and axitinib for renal cell carcinoma has been reported. Preexisting stasis dermatitis may have affected the onset and deterioration of immune‐related dermatitis.
format Online
Article
Text
id pubmed-8560444
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85604442021-11-08 Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis Imai, Shunsuke Nakamura, Masaki Chujo, Satomi Ooki, Ryousuke Inoue, Yasushi Horiuchi, Hajime Morikawa, Teppei Uchino, Keita Igarashi, Atsuyuki Shiga, Yoshiyuki IJU Case Rep Case Reports INTRODUCTION: The combination of pembrolizumab and axitinib has recently been approved as a first‐line treatment for previously untreated metastatic renal cell carcinoma. However, immune‐related adverse events are not well known. CASE PRESENTATION: A 65‐year‐old male was diagnosed with renal cell carcinoma with metastases to the brain and lungs. The patient had a medical history of stasis dermatitis. During the combined treatment of pembrolizumab and axitinib, blisters appeared on the lower extremities. Skin biopsy revealed septal panniculitis, pustules, and perivascular lymphocytic and neutrophilic infiltration of the skin, and the patient was diagnosed with immune‐related dermatitis. The dermatitis improved with oral prednisolone treatment. CONCLUSION: A case of immune‐related dermatitis during combinatorial treatment with pembrolizumab and axitinib for renal cell carcinoma has been reported. Preexisting stasis dermatitis may have affected the onset and deterioration of immune‐related dermatitis. John Wiley and Sons Inc. 2021-08-05 /pmc/articles/PMC8560444/ /pubmed/34755064 http://dx.doi.org/10.1002/iju5.12356 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Imai, Shunsuke
Nakamura, Masaki
Chujo, Satomi
Ooki, Ryousuke
Inoue, Yasushi
Horiuchi, Hajime
Morikawa, Teppei
Uchino, Keita
Igarashi, Atsuyuki
Shiga, Yoshiyuki
Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis
title Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis
title_full Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis
title_fullStr Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis
title_full_unstemmed Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis
title_short Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis
title_sort immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560444/
https://www.ncbi.nlm.nih.gov/pubmed/34755064
http://dx.doi.org/10.1002/iju5.12356
work_keys_str_mv AT imaishunsuke immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis
AT nakamuramasaki immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis
AT chujosatomi immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis
AT ookiryousuke immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis
AT inoueyasushi immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis
AT horiuchihajime immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis
AT morikawateppei immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis
AT uchinokeita immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis
AT igarashiatsuyuki immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis
AT shigayoshiyuki immunerelateddermatitisduringcombinedtreatmentwithpembrolizumabandaxitinibinapatientwithmetastaticrenalcellx92carcinomawithstasisdermatitis

Ejemplares similares